ERBB2 and breast carcinoma: The traditional factors currently used for prognostic stratification and treatment decisions in the advanced stages of breast cancer, including hormone receptor and HER2 status, site and extent of metastatic burden, and length of disease-free interval, often do not adequately predict treatment response and disease evolution.